Back to top
more

Elevance Health, Inc. (ELV)

(Delayed Data from NYSE)

$503.89 USD

503.89
921,454

+3.77 (0.75%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $504.14 +0.25 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Boston Scientific (BSX) Banks on Global Expansion, Innovation

In EMEA, Boston Scientific (BSX) is successfully expanding its base, banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand.

Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

GE HealthCare (GEHC) New Deal to Aid Its Ultrasound Portfolio

GE HealthCare (GEHC) announces that it has entered into an agreement to acquire Intelligent Ultrasound's AI software business to strengthen its ultrasound portfolio.

Hyperfine's (HYPR) Swoop System Gets New FDA-Cleared Software

Hyperfine (HYPR) announces the receipt of FDA clearance for its ninth-generation AI-powered Swoop system software.

Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense

Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.

Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance

Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Elevance Health (ELV) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Elevance Health (ELV) Surpasses Q2 Earnings and Revenue Estimates

Elevance Health (ELV) delivered earnings and revenue surprises of 1.30% and 0.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Expands Its Facility Capabilities in Germany

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.

Stryker (SYK) Completes Artelon's Acquisition to Boost Business

Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.

DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?

DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Here's Why Elevance Health (ELV) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Patterson Companies (PDCO) Aims to Streamline Patient Experience

Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.

Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?

Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.

3 Reasons Why You Should Hold McKesson (MCK) Stock for Now

McKesson's (MCK) robust Biologics business raises optimism about the stock.

What Analyst Projections for Key Metrics Reveal About Elevance Health (ELV) Q2 Earnings

Beyond analysts' top -and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Microbot Medical (MBOT) Progresses in Its Human Clinical Trial

Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.

Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists

Brookdale Senior's (BKD) weighted average occupancy for June rises 140 bps year over year.

Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Derek Lewis headshot

Tame Volatility with These 3 Low Beta Stocks

Low beta stocks can offer stabilization when combined with high-beta stocks, providing a more balanced risk profile.

UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale

By selling these assets, UnitedHealth (UNH) and Amedisys aim to avoid potential monopoly issues and ensure a smoother merger process.

Why Elevance Health (ELV) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.